Top

BMC Ophthalmology

Published in:

Open Access 01-12-2017 | Research article

Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema

Authors: Yoshiro Minami, Taiji Nagaoka, Akihiro Ishibazawa, Akitoshi Yoshida

Published in: BMC Ophthalmology | Issue 1/2017

Abstract

Background

The short-term effects of intravitreal ranibizumab (IVR) on diabetic macular edema (DME) remains unclear. We assessed the short-term effects of IVR on DME.

Methods

Eighteen eyes of 14 patients with DME were enrolled in this prospective interventional case series. After intravitreal ranibizumab was injected into treatment-naïve eyes with DME, we measured the foveal thickness (FT) before and 2 h, 1 day, 1 week, and 1 month later and the best-corrected visual acuity (BCVA) at all times except 2 h and compared the changes to baseline (ΔFT and ΔVA).

Results

The mean FT decreased significantly (p < 0.0001) from 452 ± 77 to 429 ± 65 microns after 2 h. The mean logarithm of the minimum angle of resolution BCVA improved significantly (p = 0.032) after 1 month from 0.41 ± 0.24 to 0.32 ± 0.21 (20/51 to 20/42, Snellen equivalent). The ΔFT after 2 h was significantly (r = 0.53, p = 0.025) correlated with the ΔFT after 1 month. The ΔVA after 1 day was significantly (r = 0.59, p = 0.01) correlated with the ΔVA after 1 month.

Conclusions

The structural effects of IVR for DME occurred within 2 h, whereas the functional effects occurred after 1 month. The short-term effects (within 1 day) of IVR may predict the therapeutic outcome 1 month after IVR in patients with DME.

Trial registration

The trial registration number: UMIN000026118 (Feb/13/2017). Retrospectively registered.

Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema:pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26:2653–64.CrossRefPubMed

Elman MJ, Aiello LP, Beck RW, The Diabetic Retinopathy Clinical Research Network, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.CrossRefPubMedPubMedCentral

Elman MJ, Ayala A, Bressler NM, Diabetic Retinopathy Clinical Research Network, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375–81.CrossRefPubMed

Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.CrossRefPubMed

Boyer DS, Nguyen QD, Brown DM, et al. Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE Trials. Ophthalmology. 2015;122:2504–13.CrossRefPubMed

Nguyen QD, Shah SM, Heier JS, et al. READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology. 2009;116:2175–81.CrossRefPubMed

Nguyen QD, Shah SM, Khwaja AA, READ-2 Study Group, et al. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology. 2010;117:2146–51.CrossRefPubMed

Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.CrossRefPubMedPubMedCentral

Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–62.CrossRefPubMed

10.

Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121:1045–53.CrossRefPubMed

11.

Ishibashi T, Li X, Koh A, et al. The REVEAL Study: Ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology. 2015;122:1402–15.CrossRefPubMed

12.

Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology. 1991;98:807–22.CrossRef

13.

Welch DE, Elmariah H, Peden MC, et al. Short-term response of macular oedema to intravitreal bevacizumab. Br J Ophthalmol. 2009;93:1033–6.CrossRefPubMed

14.

Ma DJ, Park KH, Woo SJ. Predicting 1-month response of macular edema to intravitreal bevacizumab from 1-h response. Can J Ophthalmol. 2014;49:267–72.CrossRefPubMed

15.

Karth PA, Chang A, Wirostko W. Paired responses to intravitreal bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2014;252:207–11.CrossRefPubMed

16.

Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology. 2015;122:1395–401.CrossRefPubMed

17.

Bressler SB, Qin H, Beck RW, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130:1153–61.CrossRefPubMedPubMedCentral

18.

Ebneter A, Wolf S, Abhishek J, Zinkernagel MS. Retinal layer response to ranibizumab during treatment of diabetic macular edema: Thinner is not always better. Retina. 2016;36:1314–23.CrossRefPubMed

19.

Ebneter A, Wolf S, Zinkernagel MS. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab. Br J Ophthalmol. 2016;100:365–70.CrossRefPubMed

20.

Ebneter A, Waldmeier D, Zysset-Burri DC, Wolf S, Zinkernagel MS. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2016;7. [Epub ahead of print]

21.

Minami Y, Nagaoka T, Ishibazawa A, et al. Short-term effect of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion. Retina. 2016;36:1726–32.CrossRefPubMed

22.

Campochiaro PA, Choy DF, Do DV, et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology. 2009;116:2158–64.CrossRefPubMed

23.

Kotsidis ST, Lake SS, Alexandridis AD, et al. 24-h variation of optical coherence tomography-measured retinal thickness in diabetic macular edema. Eur J Ophthalmol. 2012;22:785–91.PubMed

Title: Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema
Authors: Yoshiro Minami
Taiji Nagaoka
Akihiro Ishibazawa
Akitoshi Yoshida
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Ophthalmology / Issue 1/2017
Electronic ISSN: 1471-2415
DOI: https://doi.org/10.1186/s12886-017-0420-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema

Abstract

Background

Methods

Results

Conclusions

Trial registration

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2017

Ocular knowledge and practice among type 2 diabetic patients in a tertiary care hospital in Bangladesh

A retinopathy in young patient with co-inheritance of heterozygous alpha + −thalassemia and sickle trait: a case report

Telemedicine screening of retinal diseases with a handheld portable non-mydriatic fundus camera

Ten years follow-up after surgery for a foveal detachment due to optic disc pit: a case report of outer retinal layer healing

Corneal densitometry changes in a patient with interface fluid syndrome after small incision lenticule extraction

Gestational diabetes mellitus and retinal microvasculature